Abstract
Biomarkers are key for the different phases of drug development in Alzheimer Disease and in other fields. Traditionally the process of biomarker qualification has been slow, mostly exclusively academic. Regulators were mostly passive spectators. The Pharmaceutical innovation crisis of the end of XX century prompted the regulatory agencies and the governments from both sides of the Atlantic to initiate a number of programs to foster renovation, creativity and new paradigms. This created the opportunity for regulators to move from a passive position to a more active role, as facilitators. However, it is becoming apparent that there is room for even more central roles for regulators in the interactive consortia that are now in place. It is also becoming apparent that regulatory agencies are expected to become highly specialized hubs holding expert “know-how” not easily available elsewhere.
Similar content being viewed by others
References
http://www.biomarkersconsortium.org consulted January 15, 2009
Guideline on medicinal products for the treatment of Azheimer’s disease and other dementias. Doc. Ref. CPMP/EWP/553/95 Rev.
http://imi.europa.eu/documents_en.html consulted January 15, 2009
http://www.emea.europa.eu/htms/human/presub/q46.htm consulted January 15, 2009.
http://www.fda.gov/oc/initiatives/criticalpath consulted January 15, 2009.
http://www.adni-info.org/index.php consulted January 15, 2009.
http://www.fda.gov/CDER/regulatory/pharmacometrics/disease.htm consulted January 15, 2009
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sampaio, C. Biomarkers in clinical trials of Alzheimer Disease (AD): What is expected from regulatory agencies?. J Nutr Health Aging 13, 339–340 (2009). https://doi.org/10.1007/s12603-009-0035-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12603-009-0035-8